Immunocore Holdings Ltd Cash Flow Conversion Efficiency
Immunocore Holdings Ltd cash flow conversion efficiency. Based on the latest financial reports, Immunocore Holdings Ltd (IMCR) has a cash flow conversion efficiency ratio of -0.013x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.48 Million) by net assets ($419.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Immunocore Holdings Ltd market cap and net worth for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Immunocore Holdings Ltd (2013–2025)
Cash flow conversion efficiency of Immunocore Holdings Ltd from 2013 to 2025. This chart illustrates how Immunocore Holdings Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Immunocore Holdings Ltd stock price today for real-time trading data and today's change.
Immunocore Holdings Ltd Cash Flow Conversion Ratio Explained
Immunocore Holdings Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Immunocore Holdings Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immunocore Holdings Ltd ranked by their cash flow conversion efficiency. Review Immunocore Holdings Ltd free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Melco Resorts & Entertainment Ltd
NASDAQ:MLCO
|
-0.046x |
|
Globant SA
F:2G2
|
0.079x |
|
Valiant Co Ltd
SHE:002643
|
0.049x |
|
Sanbo Hospital Management Group Ltd. A
SHE:301293
|
N/A |
|
Pavilion Real Estate Inv Trust
KLSE:5212
|
0.098x |
|
Thangamayil Jewellery Limited
NSE:THANGAMAYL
|
-0.077x |
|
Guangdong Goworld Co Ltd
SHE:000823
|
0.022x |
|
Farglory Land Development Co Ltd
TW:5522
|
0.056x |
Annual Cash Flow Conversion Efficiency for Immunocore Holdings Ltd (2013–2025)
The table below shows the annual cash flow conversion efficiency of Immunocore Holdings Ltd from 2013 to 2025. Also see Immunocore Holdings Ltd assets under control for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $381.03 Million | $-7.97 Million | -0.021x | -128.95% |
| 2024-12-31 | $360.72 Million | $26.06 Million | 0.072x | +1045.38% |
| 2023-12-31 | $368.84 Million | $2.33 Million | 0.006x | +104.34% |
| 2022-12-31 | $338.90 Million | $-49.21 Million | -0.145x | +76.51% |
| 2021-12-31 | $231.53 Million | $-143.11 Million | -0.618x | +43.52% |
| 2020-12-31 | $55.35 Million | $-60.57 Million | -1.094x | +78.87% |
| 2019-12-31 | $19.57 Million | $-101.38 Million | -5.181x | -1663.12% |
| 2018-12-31 | $56.58 Million | $-16.63 Million | -0.294x | +34.53% |
| 2017-12-31 | $137.55 Million | $-61.73 Million | -0.449x | -112.84% |
| 2016-12-31 | $174.98 Million | $-36.90 Million | -0.211x | -152.40% |
| 2015-12-31 | $214.50 Million | $-17.92 Million | -0.084x | +99.56% |
| 2014-12-31 | $-2.10 Million | $39.79 Million | -18.910x | -1970.52% |
| 2013-12-31 | $11.14 Million | $11.26 Million | 1.011x | -- |
About Immunocore Holdings Ltd
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebe… Read more